1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
AtlasClear Holdings preliminarily reported fiscal 2026 revenue (year ended June 30, 2026) of about $20.1 million, up about 85% from $10.9 million, and about $21.9 million including interest income. It also expects net income of about $2.0 million, its second straight year of positive net income, though these preliminary, unaudited results may change once the audit is complete.
Total revenues of about $20.1 million, up about 85% from $10.9 million; with $1.8 million of interest income, about $21.9 million, versus $12.9 million in fiscal 2025.
Stock locate fees rose to about $6.8 million from $0.3 million; commission revenue grew about 56% to about $9.3 million.
Expected net income of about $2.0 million, including non-cash fair value gains; cash about $15.4 million and stockholders' equity about $21.1 million at June 30, 2026, versus a $6.8 million deficit a year earlier.
Results are unaudited and may differ materially; the company expects to file its 10-K and report full results by September 28, 2026.
REGENXBIO and the University of Pennsylvania agreed to settle patent infringement litigation with Sarepta Therapeutics and Catalent over Sarepta's ELEVIDYS gene therapy. Sarepta will pay REGENXBIO $39.0 million within 10 days of the settlement's effective date, and the parties will end the ongoing patent litigation.
Sarepta will pay $39.0 million to REGENXBIO within 10 days of the settlement's effective date.
The settlement covers U.S. Patent No. 10,526,617 and U.S. Patent No. 11,680,274, related to SRP-9001 (ELEVIDYS).
REGENXBIO and UPenn release current infringement claims and agree to a covenant not to sue for future claims on AAVrh74-based Sarepta gene therapy products.
The full agreement is expected to be filed with the Form 10-Q for the quarter ending September 30, 2026.
Greenland Technologies Holding Corporation received a Nasdaq letter on September 22, 2026 confirming it has regained compliance with the $1.00 minimum bid price requirement. The company's Class A ordinary shares closed at $1.00 or above for 10 consecutive business days from September 8 through September 21, 2026, and Nasdaq has closed the matter. For shareholders, this removes the risk of delisting over the bid price issue.
Nasdaq notified the company on March 12, 2026 that its Class A ordinary shares had closed below $1.00 for 30 consecutive business days
On September 10, 2026, Nasdaq granted an additional 180-day period, to March 8, 2027, to regain compliance
On September 22, 2026, Nasdaq confirmed compliance after 10 consecutive business days at or above $1.00, from September 8 through September 21, 2026
Holley made a voluntary $10 million prepayment of principal on its first lien term loan facility on September 22, 2026, and announced it in a press release on September 23. The company says total debt repayments since September 2023 reach $125 million, funded entirely by free cash flow, and that it remains on track for year-end leverage below 3.5x.
Voluntary prepayment of $10 million on first lien term loan made September 22, 2026
Total debt repaid since September 2023 is $125 million, funded by free cash flow
Total Leverage Ratio reduced from a peak of 5.67x; year-end target below 3.5x and long-term target of approximately 3.0x
Cumulative debt reductions generate approximately $5 million in annualized net interest savings
Paychex reported first-quarter fiscal 2027 results for the three months ended August 31, 2026, with total revenue up 6% to $1.6 billion and diluted earnings per share up 14% to $1.21. The company raised its fiscal 2027 outlook for PEO and Insurance Solutions revenue growth to 7% to 8% and left most other guidance unchanged, including adjusted diluted EPS growth of 7% to 9%.
Total revenue rose 6% to $1.6 billion; operating income rose 14% to $619.2 million.
Adjusted diluted EPS rose 10% to $1.34; GAAP diluted EPS rose 14% to $1.21.
PEO and Insurance Solutions revenue growth outlook raised to 7% to 8% from 6% to 7%; interest on funds held for clients outlook raised to $200 million to $210 million.
Paid dividends of $1.19 per share totaling $424.1 million in the quarter; cash flow from operations was $413.5 million, down from $718.4 million a year earlier.
Cintas reported first-quarter fiscal 2027 revenue of $3.01 billion, up 10.9%, and diluted EPS of $1.36, up 13.3% from a year earlier. The company raised its full-year revenue and adjusted EPS guidance, though the results include $14.4 million of transaction expenses tied to the proposed UniFirst acquisition, which is still under review by the U.S. Federal Trade Commission.
First-quarter revenue of $3.01 billion, up 10.9%; organic revenue growth of 8.9%
Diluted EPS of $1.36 vs. $1.20 a year earlier; adjusted diluted EPS of $1.39, up 15.8%
Fiscal 2027 revenue guidance raised to $12.15 billion to $12.27 billion; adjusted diluted EPS guidance raised to $5.45 to $5.54
UniFirst transaction expenses of $14.4 million; closing expected before the end of calendar 2026
Armata Pharmaceuticals said it received $3.7 million in additional non-dilutive funding from the U.S. Department of War to support the Phase 3 program for AP-SA02, its lead clinical candidate. The company said this is the first DoW funding specifically for Phase 3 execution, and it lifts cumulative non-dilutive DoW support for the program to approximately $32.4 million, which may reduce the need to raise capital through share sales.
Armata received $3.7 million in additional non-dilutive funds from the U.S. Department of War, announced September 23, 2026.
The award is administered through the Medical Technology Enterprise Consortium and funded by the Defense Health Agency and Joint Warfighter Medical Research Program.
Cumulative non-dilutive DoW funding under the award is approximately $32.4 million, following $28.7 million previously provided.
The company plans to start a Phase 3 superiority study of AP-SA02 in complicated S. aureus bacteremia in the second half of 2026.
Ionis and partner Roche reported positive prespecified interim results from the ongoing Phase 3 IMAgINATION study of investigational sefaxersen in adults with primary IgA nephropathy. The study met its primary endpoint, with statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, and no new safety signals were identified. The results advance a candidate that Roche licensed from Ionis, and Ionis is eligible for regulatory and sales milestone payments and royalties under that agreement.
Primary endpoint met: statistically significant reduction in 24-hour urine protein-to-creatinine ratio versus placebo at 37 weeks
Study enrolled 459 people, randomized 1:1 to sefaxersen or placebo for 105 weeks
Safety and tolerability were consistent with previously reported data, with no new safety signals
The study continues as a blinded study to assess change in eGFR at week 105; interim data will be presented at an upcoming medical congress, date not given
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.